Why the study?
Does intracerebroventricular TRV027 lower blood pressure and alter fluid intake in a mouse model of DOCA-salt hypertension?
Population
Mice subjected to deoxycorticosterone acetate (DOCA)-salt hypertension, and a neuronal cell line.
Comparison
Intracerebroventricular administration of… vs Intracerebroventricular vehicle or losartan…
Design
Preclinical
Key result
Central administration of the β-arrestin-biased agonist TRV027 increased aversion to saline and significantly reduced blood pressure and heart rate in mice with DOCA-salt hypertension.
Authors
Loading...
May support central β-arrestin-biased AT1R agonism in salt-sensitive hypertension; leaves open translation to humans.
Does intracerebroventricular TRV027 lower blood pressure and alter fluid intake in a mouse model of DOCA-salt hypertension?
Central administration of the AT1R β-arrestin-biased agonist TRV027 increases saline aversion and lowers blood pressure in a mouse model of salt-sensitive hypertension, suggesting a potential therapeutic role for selective AT1R β-arrestin pathway activation.
Zanaty et al. (2020) studied Deoxycorticosterone acetate (DOCA)-salt hypertension. TRV120027 (TRV027) vs. Vehicle or losartan was evaluated on Relative intake of water versus saline solutions and blood pressure. Central administration of the β-arrestin-biased agonist TRV027 increased aversion to saline and significantly reduced blood pressure and heart rate in mice with DOCA-salt hypertension.